These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36453516)

  • 41. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
    Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
    Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(7):1-52. PubMed ID: 27099643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
    Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
    Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
    Kikuchi M; Tanaka J; Kondo T; Hashino S; Kasai M; Kurosawa M; Iwasaki H; Morioka M; Kawamura T; Masauzi N; Fukuhara T; Kakinoki Y; Kobayashi H; Noto S; Asaka M; Imamura M
    Int J Hematol; 2010 Oct; 92(3):481-9. PubMed ID: 20830615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study.
    Bartram J; Wright G; Adams S; Archer P; Brooks T; Edwards D; Hancock J; Knecht H; Inglott S; Mountjoy E; Roynane M; Wakeman S; Moppett J; Hubank M; Goulden N
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29513. PubMed ID: 34971078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia].
    Mizutani Y; Kusakabe S; Fukushima K; Murakami H; Hamada M; Hasegawa C; Mizuta E; Yamaguchi Y; Nakai R; Kurashige R; Hino A; Ueda T; Fujita J; Miyamura T; Hosen N
    Rinsho Ketsueki; 2024; 65(2):78-83. PubMed ID: 38448002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
    Chen X; Gao Q; Roshal M; Cherian S
    Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
    Jabbour E; Haddad FG; Short NJ; Senapati J; Jain N; Sasaki K; Jorgensen J; Wang SA; Alvarado Y; Wang X; DiNardo C; Masarova L; Kadia T; Garris RS; Ravandi F; Kantarjian H
    Blood; 2024 Feb; 143(5):417-421. PubMed ID: 37879077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of minimal residual disease evaluation in leukemia therapy.
    Campana D
    Curr Hematol Malig Rep; 2008 Jul; 3(3):155-60. PubMed ID: 20425460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
    Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
    Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
    Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
    Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
    Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
    Semchenkova A; Zhogov V; Zakharova E; Mikhailova E; Illarionova O; Larin S; Novichkova G; Karachunskiy A; Maschan M; Popov A
    Int J Lab Hematol; 2023 Aug; 45(4):506-515. PubMed ID: 36871952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
    Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
    Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond.
    Dekker SE; Leonard J; Muffly L
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):878-882. PubMed ID: 36130863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.